Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Combination Study of Antibiotics With Enzalutamide (PROMIZE) — Stella

Home/Metastatic Castration-Resistant Prostate Cancer (mCRPC)/Combination Study of Antibiotics With Enzalutamide (PROMIZE)

View on ClinicalTrials.gov

Recruiting

Back to Metastatic Castration-Resistant Prostate Cancer (mCRPC) trials

Combination Study of Antibiotics With Enzalutamide (PROMIZE)

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(2 sites)

Switzerland

Oncolgy Institute of Southern Switzerland (IOSI), Bellinzona

United Kingdom

The Royal Marsden NHS Foundation Trust, Sutton

Key details

Phase

Early testing / Safety & dosing

Sponsor

Institute of Cancer Research, United Kingdom

Collaborators

Prostate Cancer Foundation

Enrollment target

~39 participants

Started

November 2023

Primary completion

June 2026

Age range

18 Years and older

Sex

Male only

Last updated November 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.